Non-Communicable DiseaseNCT03473795
Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes
An observational study of Non-Communicable Disease, run by Memorial Sloan Kettering Cancer Center at 14 sites in 2 countries.
Trial summary
This umbrella protocol seeks to develop robust data registries for non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) with the aim of providing accurate and comprehensive data for the evaluation of such diseases in sub-Saharan African countries.Healthy volunteers will be included in the study for comparison. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Non-Communicable Disease
- What is being tested?
- Questionnaire forms and Bio-specimen samples
- Type of treatment
- Lifestyle or therapy programme
- How many people
- 6,990 participants
- Where
- 14 sitesin 2 countries
- Study dates
- 16 Mar 2018to Mar 2027
- How long will I take part?
- 5 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Participants will be accrued in medical clinics in Africa as determined by the local investigators and local research staff.
Who may be able to join
- Age 18 and older.
- Suspected or confirmed diagnosis of a non-communicable disease. OR
- Healthy volunteers/no confirmed diagnosis for comparison.
Who cannot join
- Participants unwilling to sign consent.
- Participants under the age of 18
Trial locations and contacts
14 sites in 2 countries.
14 sites in 2 countries
Nigeria13 sites
National Hospital of Abuja (Data collection only)
Abuja, Central Business District, 900103
University Of Nigeria Teaching Hospital (UNTH) Ituku-Ozalla Enugu
Enugu
University College Hospital
Ibadan, Oyo State
Lagos State University Teaching Hospital
Idi-Araba, Lagos
Lagos State University Teaching Hospital
Ikeja
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC)
Ile-Ife
University of Ilorin Teaching Hospitals
Ilorin
University of Maiduguri Teaching Hospital (Data collection only)
Maiduguri, 600104
Ladoke Akintola University of Technology
Ogbomoso, Oyo State
Ondo State Trauma and Surgical Centre
Ondo
Federal Medical Centre Owo
Owo, Ondo State
Federal Medical Centre Owo
Owo
Olabisis Onabanjo University Teaching Hospital
Sagamu, Ogun State
United States1 site
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
About this study
Official title: Developing Non-Communicable Disease Registries in Africa: A Step Towards Providing Quality Data for Improving Patient Outcomes
This umbrella protocol seeks to develop robust data registries for non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) with the aim of providing accurate and comprehensive data for the evaluation of such diseases in sub-Saharan African countries.Healthy volunteers will be included in the study for comparison.
Additionally, the investigators aim to describe the gut microbiome community diversity of a cohort of community dwelling Nigerians and compare with CRC patients in Nigerian and at MSK. We will collect stool for microbiome and metabolomic analysis from community dwelling persons in the catchment area of ARGO facilities in Nigeria while contemporaneously administering an extensive medical and environmental exposure questionnaire.
- Conditions
- Non-Communicable Disease
- Being tested
- Questionnaire forms, Bio-specimen samples
- Keywords
- Patient Outcomes, 18-114
- Medical subject headings
- Noncommunicable Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Questionnaire formsBehavioural
The questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality.
Bio-specimen samplesOther
Samples can include tissue, blood, urine, saliva, hair and nail clipping.
| Study group | Role | What they receive |
|---|---|---|
| healthy participants and participants diagnosed with NCDs | This protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls. Receives: Behavioral: Questionnaire forms; Other: Bio-specimen samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
# of patients that develope non-communicable diseases in Africa
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Mar 2018
- Study start16 Mar 2018
- Primary completionMar 2027 (estimated)
- Study completionMar 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Communicable DiseaseStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Enrolment
- 6,990 participants (actual)
- Target duration
- 5 Years
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- Duke University, Johns Hopkins University
- Responsible party
- Sponsor
- Investigators
- T. Peter Kingham, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03473795
- Sponsor's protocol ID
- 18-114
- Status last verified
- Aug 2026
- First submitted
- 16 Mar 2018
- Last updated
- 18 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Developing Non-Communicable Disease Registries in Africa: A Step Towards Providing Quality Data for Improving Patient Outcomes
- ClinicalTrials.gov ID
- NCT03473795
- Acronym / sponsor ID
- 18-114
- Conditions
- Non-Communicable Disease
- Keywords
- Patient Outcomes, 18-114
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 6,990 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- Duke University, Johns Hopkins University
- Study start
- 16 Mar 2018 (actual)
- Primary completion
- Mar 2027 (estimated)
- Study completion
- Mar 2027 (estimated)
- First posted
- 22 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This umbrella protocol seeks to develop robust data registries for non-communicable diseases (NCDs) in sub-Saharan Africa (SSA) with the aim of providing accurate and comprehensive data for the evaluation of such diseases in sub-Saharan African countries.Healthy volunteers will be included in the study for comparison.
Additionally, the investigators aim to describe the gut microbiome community diversity of a cohort of community dwelling Nigerians and compare with CRC patients in Nigerian and at MSK. We will collect stool for microbiome and metabolomic analysis from community dwelling persons in the catchment area of ARGO facilities in Nigeria while contemporaneously administering an extensive medical and environmental exposure questionnaire.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Prospective
- Target follow-up
- 5 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| healthy participants and participants diagnosed with NCDs | – | Behavioral: Questionnaire forms, Other: Bio-specimen samplesThis protocol will entail prospective collection of data on healthy participants and participants diagnosed with NCDs managed at collaborating institutions in SSA. Information to be obtained includes socio-demographic data, risk factors, disease-specific data, investigation and treatment details, as well as findings during follow-up. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. Follow-up data will be updated during clinic visits and also via phone calls. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Participants will be accrued in medical clinics in Africa as determined by the local investigators and local research staff.
Key inclusion criteria (3 listed)
- Age 18 and older.
- Suspected or confirmed diagnosis of a non-communicable disease. OR
- Healthy volunteers/no confirmed diagnosis for comparison.
Key exclusion criteria (2 listed)
- Participants unwilling to sign consent.
- Participants under the age of 18
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Questionnaire formsThe questionnaires will include information such as socio-demographic data, risk factors, disease specific data, investigation and treatment details as well as findings during followup. Particular reference will be made to outcome measures such as local and distant recurrence, survival and mortality. | Behavioural | healthy participants and participants diagnosed with NCDs |
| Bio-specimen samplesSamples can include tissue, blood, urine, saliva, hair and nail clipping. | Other | healthy participants and participants diagnosed with NCDs |
Primary outcome
# of patients that develope non-communicable diseases in Africa
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Non-Communicable Disease
Active, not recruiting
Acute Non-severe Osteomyelitis in Children - Outpatient Management Strategy With Oral Antibiotic Therapy Compared to a Standard Strategy With Conventional Hospitalization and Intravenous Antibiotic Therapy: a Randomized Open-label Non-inferiority Study With Bayesian and Medical-economic Analyses.
Osteomyelitis
RecruitingObservational study
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Not yet recruitingPhase 4
Oral Switch in Bloodstream Infections in Immunocompromised Children
Bloodstream Infection, Bloodstream Infection Due to Central Venous Catheter
Recruiting
Safety and Efficacy of NTP in Thyroid Surgery: Pilot Study on Morbidity Prevention and Adjuvant Oncological Control
Thyroid Diseases, Wound Healing
RecruitingPhase 3
Keverprazan-Minocycline Dual Therapy of Different Durations Versus Bismuth Quadruple Therapy for Helicobacter Pylori Eradication.
Helicobacter Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
T. Peter Kingham, MD principal investigator
Memorial Sloan Kettering Cancer Center
14 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Non-Communicable Disease, run by Memorial Sloan Kettering Cancer Center at 14 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 14 sites in Nigeria, United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
# of patients that develope non-communicable diseases in Africa (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.